Biopharma Due Diligence

A global biopharma company was evaluating an acquisition whose potential indications ranged from gastrointestinal disorders to ophthalmology. With a key leader out on vacation and the deadline for a non-binding term sheet drawing near, the company’s head of Commercial Business Development turned to Business Talent Group.

In the span of a few days, we delivered a two-person team to help the company extend and finalize its commercial evaluation. A biotech investment specialist customized a model that looked at multiple scenarios and helped size patient populations across different indications. An analyst assessed market access and competitive dynamics. A week later, the team had the figures it needed to make a successful bid; they are now proceeding to the next phase of the acquisition.

About the Author

Leah Hoffmann

Leah Hoffmann is a former journalist who has worked for Forbes.com and The Economist. She is passionate about clear thinking, sharp writing, and strong points of view.

More Content by Leah Hoffmann
Previous Article
Assessing New Recycling Models
Assessing New Recycling Models

The baby care division at a global consumer goods company was assessing the feasibility of a new approach t...

Next Article
Reinventing Consulting at an F200 Biopharma Company
Reinventing Consulting at an F200 Biopharma Company

Leaders at this biopharma giant didn’t set out to reinvent the way the company sourced industry experts and...

×

Talk with BTG to learn more about our on-demand talent.

First Name
Last Name
Company
Country
I would like to receive the latest expert insights and news from Business Talent Group.
By registering, you agree to the processing of your personal data by Business Talent Group as described in the Privacy Statement.
View our Privacy Policy and Cookie Policy
Thank you! We will be in touch shortly.
Error - something went wrong!